Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma
- 9 April 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 61 (8), 1850-1859
- https://doi.org/10.1080/10428194.2020.1747066
Abstract
In the randomized phase-3 OPTIMISMM study, the addition of pomalidomide to bortezomib and low-dose dexamethasone (PVd) resulted in significant improvement in progression-free survival (PFS) in lenalidomide-pretreated patients with relapsed or refractory multiple myeloma (RRMM), including lenalidomide refractory patients. Here, we report health-related quality of life (HRQoL) results from this trial. Patients received PVd or Vd in 21-day cycles until disease progression or discontinuation. HRQoL was assessed using the EORTC QLQ-C30, QLQ-MY20, and EQ-5D-3L instruments on day 1 of each treatment cycle. Mean score changes for global QoL, physical functioning, fatigue, side effects of treatment domains, and EQ-5D-3L index were generally stable over time across treatment arms. The proportion of patients who experienced clinically meaningful worsening in global QoL and other domains of interest was similar. These HRQoL results with PVd along with previously demonstrated improvement in PFS vs Vd continue to support its use in patients with RRMM.This publication has 39 references indexed in Scilit:
- Global Burden of Multiple MyelomaJAMA Oncology, 2018
- Going the distance: Are we losing patients along the multiple myeloma treatment pathway?Critical Reviews in Oncology/Hematology, 2018
- A question of class: Treatment options for patients with relapsed and/or refractory multiple myelomaCritical Reviews in Oncology/Hematology, 2017
- Multiple myeloma: patient outcomes in real‐world practiceBritish Journal of Haematology, 2016
- Pathogenesis beyond the cancer clone(s) in multiple myelomaBlood, 2015
- Health‐related quality of life and disease‐specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population‐based study using the PROFILES registryEuropean Journal of Haematology, 2012
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group studyLeukemia, 2011
- Multiple MyelomaThe New England Journal of Medicine, 2011
- Clinical Course of Patients With Relapsed Multiple MyelomaMayo Clinic Proceedings, 2004
- Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differencesEuropean Journal of Haematology, 2004